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Introduction: Optimizing radiotherapy with or without chemotherapy through advanced imaging and accelerated radiation schemes shows promising results in locally advanced
non–small-cell lung cancer (NSCLC). This study compared the cost-effectiveness of positron emission tomography-computed tomography based isotoxic accelerated sequential
chemo-radiation (SRT2) and concurrent chemo-radiation with daily low-dose cisplatin (CRT2) with standard sequential (SRT1) and concurrent chemo-radiation (CRT1).
Methods: We used an externally validated mathematical model to simulate the four treatment strategies. The model was built using data from 200 NSCLC patients treated with
curative sequential chemo-radiation. For concurrent strategies, data from a meta-analysis and a single study were included in the model. Costs, utilities, and resource use estimates
were obtained from literature. Primary outcomes were the incremental cost-effectiveness and cost-utility ratio (ICUR) of each strategy. Scenario analyses were carried out to
investigate the impact of uncertainty.
Results: Total undiscounted costs and quality-adjusted life-years (QALYs) for SRT1, CRT1, SRT2, and CRT2 were EUR 17,288, EUR 18,756, EUR 19,072, EUR 17,360 and QALYs
1.10, 1.15, 1.40, and 1.40, respectively. Compared with SRT1, the ICURs were EUR 38,024/QALY for CRT1, EUR 6,249/QALY for SRT2, and EUR 346/QALY for CRT2. CRT2
was highly cost-effective compared with SRT1. Moreover, CRT2 was more effective and less costly than CRT1 and SRT2. Therefore, these strategies were dominated by CRT2.
Conclusion: Optimized sequential and concurrent chemo-radiation strategies are more effective and cost-effective than the current conventional sequential and concurrent strategies.
Concurrent chemo-radiation with a daily low dose cisplatin regimen is the most cost-effective treatment option for locally advanced inoperable NSCLC patients.
Keywords: Cost-effectiveness, Modeling, Chemo-radiation, Radiotherapy, Lung cancer
Lung cancer remains a major cause of death worldwide with
over 1 million deaths a year (1). Non–small-cell lung cancer
(NSCLC) represents 80 percent of all lung tumors. Approxi-
mately 35 percent of the patients presents with locally advanced
nonmetastatic disease. In The Netherlands, this amounts to
roughly 1,000 NSCLC patients yearly presenting with inoper-
able stage III disease. These patients are mostly treated with
(chemo-) radiotherapy with curative intent. According to the
Dutch guidelines, treatment with concurrent chemotherapy and
radiotherapy is preferred if patients are considered fit enough,
while sequential treatment ought to be considered for frailer or
older patients (2).
Overall, 55 percent of Dutch inoperable stage III patients
receive concurrent chemo-radiotherapy, versus 45 percent se-
This research was performed within the framework of CTMM, the Center for Translational
Molecular Medicine, project AIRFORCE (grant 03O-103). Study sponsors had no role in the
design of the study, the execution of the project, or the writing of the manuscript.
quential treatment. There is level I evidence that concurrent
chemo-radiotherapy decreases local recurrences and mortality
compared with sequential chemo-radiotherapy. However, con-
current chemo-radiotherapy is substantially more burdensome
for patients than sequential chemo-radiotherapy, resulting in
more acute esophagitis and hematological toxicity (3). In ad-
dition, recommendations for concurrent chemo-radiotherapy
are based on pooled analysis of trials with relatively fit pa-
tients with minimal co-morbidities (4). These patients are not
representative of the typical NSCLC patient population. Fi-
nally, new developments in chemo-radiotherapy necessitate a
renewed evaluation of the optimal treatment choice.
Because of technical developments in radiotherapy treat-
ment planning and delivery, it became possible to deliver iso-
toxic dose prescriptions, whereby doses of radiotherapy are in-
dividualized according to the constraints of the organs at risk
(4). In addition, PET-imaging is used to guide tumor delineation
as tumor activity of the primary tumor and the affected lymph
nodes are more accurately visualized compared with CT-scans.
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Pilot studies have shown the benefits of such individualized ra-
diation schemes. Further optimization of radiotherapy, obtained
by means of accelerated and hyperfractioned schemes, has been
shown to improve 5-year survival in nonconcurrent schedules
(5).
In addition, there is a focus on optimization of the
chemotherapy schemes to minimize toxicity while maintaining
the beneficial effect of a concurrent scheme on local control
and overall survival. Koning et al. (2013) found that a concur-
rent scheme with a daily low-dose cisplatin reduced toxicity
as compared to standard doublet cisplatin-based chemotherapy
while maintaining activity (6).
Different sequential and concurrent chemo-radiotherapy
schemes have been studied in diverse trials with different in-
clusion criteria. Therefore, direct comparison of the health out-
comes is not possible. However, mathematical modeling gives
the opportunity to bring together different treatment schemes
in one consistent framework, to compare health effects, while
correcting for differences in patient population. In essence, un-
der a set of explicit assumptions, a mathematical model can be
used to simulate outcomes of a randomized trial where this has
not been done in actuality (7).
With the increasing costs of cancer care and limited
resources available, it is important to consider the cost-
effectiveness of new treatments to support decision-making.
In this study, we used a NSCLC micro-simulation model that
we developed and described previously (8). Transitions in the
micro-simulation model depend on a set of patient and tumor
features, which makes it possible to simulate patient popula-
tions with a different case-mix. The micro-simulation model
was used to obtain 3-year health and cost predictions under dif-
ferent concurrent and sequential chemo-radiation schemes.
METHODS
The aim of this study was to compare health outcomes and costs
of four different sequential and concurrent chemo-radiotherapy
strategies. We used an externally validated micro-simulation
model, built using observational data. This model was previ-
ously used to assess the cost-effectiveness of PET-based iso-
toxic accelerated radiotherapy treatment, either alone or with
sequential chemotherapy, compared with conventional (CT-
based) fixed dose radiotherapy (9). For the current study, this
model was adapted, such that the model could be used to eval-
uate other chemo-radiotherapy strategies.
The Chemo-radiotherapy Strategies under Evaluation
We compared the following sequential and concurrent chemo-
radiotherapy strategies: (i) Sequential chemo-radiotherapy
(SRT1): After chemotherapy, patients received a radiation dose
of 60 Gy, in once-daily 2 Gy fractions, 5 times per week.
(ii) Concurrent chemo-radiotherapy (CRT1): Patients received
radiotherapy concurrently with chemotherapy. Radiotherapy
Figure 1. Model predictions of OS when using the best fitting set of parameters resulting from the calibration
procedure for CRT1 and CRT2 (dotted lines), as well as the calibration targets used (solid lines). Note that
for the calibration procedure as well as for the internal validation, the case-mix of patients in the simulated
cohort is similar to the case-mix of patients in the original data source.
started at the beginning of the second course of chemother-
apy with a dose of 60 Gy, in daily 2 Gy fractions, 5 times per
week. (iii) Sequential isotoxic accelerated chemo-radiotherapy
(SRT2): After chemotherapy, patients received a radiation dose
of 54.0–79.2 Gy, delivered in 1.8 Gy fractions, twice daily. The
term isotoxic refers to the individualization of the exact radia-
tion dose according to the constraints of the organs (lungs and
spinal cord) at risk. The mean overall treatment time was 25
days. (iv) Concurrent accelerated chemo-radiotherapy (CRT2):
Patients received 66 Gy in once-daily 2.75 Gy fractions in a
mean overall treatment time of 32 days. In addition, patients
received cisplatin (6 mg/m2) 1–2 hours before each fraction.
The first two treatment strategies (SRT1 and CRT1) are
conventional strategies, in the sense that they reflect current
common practice. SRT2 represents an individualized, opti-
mized, radiotherapy scheme, and CRT2 a treatment scheme
with an unusually low daily dose of chemotherapy to minimize
toxicity. Patients that received isotoxic radiotherapy (SRT2)
were assumed to receive an additional PET-CT scan for treat-
ment planning in the treatment position.
Model Description
The model contains four clinical states from alive to death,
with intermediate states “local recurrence” and “distant metas-
tasis,” and allows five possible transitions. Supplementary
Figure 1 presents the structure of the model. All patients start
in state “Alive,” where they received treatment. Over time, they
can develop a local recurrence “LR” (transition 1), a distant
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metastasis “DM” (transition 2), or they can die without the de-
tection of a LR or DM “Death” (transition 3). After if they move
to LR or DM, they are again at risk for Death (transition 4 and
5, respectively).
The model simulates the disease trajectories of individual
patients by repeatedly sampling a patient profile, consisting of
patient and tumor characteristics (WHO performance status,
gross tumor volume [GTV], N status, sequentially treated with
chemotherapy) that are randomly drawn from prespecified cor-
related distributions. Once a specific individual patient profile
is drawn, progression to subsequent health states in the model
is simulated under a given treatment. The transitioning of pa-
tients between health states is governed by personalized hazard
rates. These hazard rates consist of a baseline time-dependent
hazard that is the same for each individual, and a personal time-
independent hazard rate ratio (HR) that varies according to the
characteristics of the sampled patient profile and the treatment
given. These parameters were estimated using statistical mod-
eling (8), as described in more detail in Supplementary Table 1
and illustrated in Supplementary Figures 2 and 3. Probabilities
to acquire different toxicities were included in the model (10–
12). Model parameters are presented in Table 1. The time hori-
zon was 3 years. Model predictions for overall survival were
internally validated for each of the four strategies. The ini-
tial micro-simulation model was validated externally for overall
survival (8). The micro-simulation model was programmed in
Excel 2003 and the Visual Basic Editor 2003.
Data Used for Model Quantification
The original micro-simulation model was built using data of
200 NSCLC patients with inoperable stage I-IIIB receiving cu-
rative radiotherapy. Patients in the dataset were referred to the
Maastro Clinic in Maastricht, The Netherlands, between 2002
and 2009. Data were collected prospectively (13). Patients in
the dataset received either conventional radiotherapy (accord-
ing to the scheme of SRT1) or PET-CT-based accelerated ra-
diotherapy (scheme as in SRT2), with or without induction
chemotherapy. Patients in the data for SRT1 and SRT2 were
stage I–III patients, in contrary to the patients in the literature
(CRT1 and CRT2), which were mainly stage III patients. How-
ever, the proportion of patients in the Maastro clinic that were
stage I–II was 15 percent only. The distribution of patients per
strategy is presented in Supplementary Table 2.
Model parameters were estimated by multi-state statistical
modeling, using conventional radiotherapy as the comparator
strategy. That means that five HRs, one for each of the five
possible transitions in the model, specify the effect of PET-
CT-based accelerated radiotherapy relative to the comparator
strategy. As the addition of chemotherapy was included as a co-
variate in the model, sequential chemo-radiotherapy strategies
could be simulated with the model. Because the model was not
developed for simulation of concurrent chemo-radiotherapy,
the five HRs for both CRT1 and CRT2, specifying the treat-
ment effect relative to the comparator strategy (SRT1), were
obtained by calibration of model output against either the liter-
ature or study data, as described below (14).
Model Calibration to Quantify Treatment Effect of the Concurrent Strategies
Model calibration involves systematic adjustment of model pa-
rameters such that model-predicted outcomes correspond to ob-
served outcomes. For the two treatment strategies CRT1 and
CRT2, the five HRs, specifying the treatment effect relative
to SRT1 for each of the five possible transitions in the model
could not be estimated directly from patient-level data. There-
fore, calibration was used to obtain estimates for these HRs.
That is, for CRT1 and CRT2, respectively, we repetitively drew
random sets of values for the 5 HRs from within a plausible
range. Subsequently, the model was used to generate predic-
tions of 1-, 2-, and 3-year survival.
These were directly compared with observed survival out-
comes by calculating the sum of squared errors of the differ-
ences in survival. The best fitting set was defined as the set
of HRs that minimizes this sum of squared errors. For CRT1
and CRT2, respectively, model-predictions were compared with
survival outcomes taken from a meta-analysis and from one
particular study (15;16). The study that informed CRT2 pro-
vided information on baeline characteristics of the population
investigated and observed toxicities under CRT2. In addition,
the authors provided us with additional information on 1-,
2-, and 3-year survival. Observations for the proportions of lo-
cal recurrence and metastasis were not available for all strate-
gies, thus the model was calibrated to fit overall survival only.
For more details on the calibration, we refer to Supplementary
Table 3.
Table 1 shows the best fitting sets of HRs for CRT1 and
CRT2 that were the result of the calibration procedure. Figure 1
shows the fit of the model predictions against the calibration
targets for both CRT1 and CRT2. Validation of the model for
the sequential treatment strategies is also described in Supple-
mentary Table 3 and depicted in Supplementary Figure 4.
Inclusion of Toxicities in the Model
For the probability to acquire dysphagia, the micro-simulation
model included a statistical ordered logit model with the covari-
ates “N-stage” and “±isotoxic.” Setting “±isotoxic” to either 0
(SRT1) or 1 (SRT2) produces risk estimates to acquire dyspha-
gia for both treatment strategies. The risk to acquire no or a spe-
cific grade of dyspnea in the model was based on probabilities
directly derived from the data for SRT1 and SRT2, respectively
(10;11). Because no data were available to estimate the occur-
rence of dyspnea and dysphagia in CRT1 and CRT2, literature
was used (3;16). For the concurrent schemes, the hematological
toxicities neutropenia and anemia were added to the model (3).
See Supplementary Table 1 for further details.
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Table 1. List of Model Parameters for Disease Progression and Toxicity
Hazard ratios for each transition (point estimate, SE)
Multi-state model 1: Alive to LR 2: Alive to DM 3: Alive to death 4: LR to death 5: DM to death Source
WHO (≥2 versus 0/1) 2,34 (0,5) 2,31(0,32) 1,72 (0,45)
N stage (≥2 versus 0/1) 0,75 (0,43) 1,51 (0,27) 2,98 (0,35)
SRT2 0,47 (0.41) 0,10 (0,37) 0,40 (0,33) 0,70 (0,44) 0,87 (0,23) Data (13)
CRT1 0,71 0,92 0,70 0,66 0,84 (3)
CRT2 1,70 0,28 0,16 0,29 0,84 (16)
Chemotherapy 2,37 (0,00) 3,21 (0,00) 0,60 (0,00)
GTV (per 10 cc) 1,01 (0,47) 1,02 (0,34) 1,03 (0,34)
Probabilities
Toxicities Dysphagia≥ grade 3 Dyspnea≥ grade 3 Neutropenia≥ grade 3 Anemia≥ grade 3 Source (year)
SRT1 0,02 0,05 0,49 0,21 Data (13), (3)
SRT2 0,05 0,10 0,49 0,21 Data (13), (3)
CRT1 0,26 0,04 0,64 0,17 (3)
CRT2 0,15 0,07 0,03 0,00 (16)
Proportion of dyspnea that is irreversible 0,71 (4)
SRT1, conventional sequential chemo-radiation; CRT1, conventional concurrent chemo-radiation; SRT2, sequential PET-CT-based isotoxic accelerated chemo-radiation; CRT2, con-
current chemo-radiation with daily low-dose cisplatin administration and daily radiation.
SE, standard error; WHO, WHO performance status; N stage, number of lymph nodes affected; GTV, gross tumor volume; LR, local recurrence; DM, metastasis.
Costs and Health-Related Quality of Life
We performed the analysis from the health care setting of the
Netherlands, using a health system perspective for the cost-
effectiveness analysis. That is, we included costs of radio-
chemotherapy, cost of treating adverse events, and all related
costs, such as hospital admission, medication, and follow-up
visits (17–21). Costs of chemotherapy were based on the treat-
ment schemes presented in the literature. Per scheme we calcu-
lated the vials needed for a patient with an average body sur-
face of 1.7 m2. For the daily dose cisplatin administration, the
infusion takes approximately 1 hour daily. In Supplementary
Table 4, a detailed overview of the costs of chemotherapy is
provided. For SRT2, costs of an additional PET-scan were in-
cluded. All costs were standardized to 2014 Euros, using the
consumer price index.
To estimate quality of life, we used utility estimates de-
rived from the literature (17;22;23). Once a patient in the model
obtained anemia, neutropenia, dysphagia, or dyspnea grade 3,
or dyspnea and dysphagia grade 2 simultaneously, a disutility
value of 0.353 was assigned for the duration of the adverse
events. Duration of both dyspnea and dysphagia was fixed at
30 days. Severe dyspnea is assumed to be irreversible for 71
percent of the patients. For those patients, we assumed that
quality of life was decreased by the disutility value for adverse
events of 0.353 for the entire time horizon in the model. A full
overview of resource use, costs, (dis)utilities, and the sources
we used is presented in Table 2.
Base-Case Analysis
For the base-case analysis, the disease history of a hypothetical
cohort of patients under all four strategies was simulated with
a distribution of baseline clinical features and tumor features
as observed in the database from the Maastro Clinic for non-
metastatic NSCLC patients ineligible for surgery, that received
(sequential chemo-)radiotherapy with curative intent (18). Pa-
tients in the simulation had a relatively good WHO perfor-
mance status (88 percent had a status of 0 or 1), 75 percent
of patients had two or more lymph nodes affected and the mean
GTV was 77 cc3. In all strategies, the distribution of clinical
and tumor features was held constant to eliminate bias due to
difference in baseline characteristics.
Model predictions were obtained by simulating the health
trajectories of a cohort of 50,000 patients from the moment
they start treatment until they die or have reached the time-
horizon of 3 years. This time horizon was chosen because
it was deemed appropriate to cover the health benefits and
costs of radiotherapy in NSCLC. Additionally, in the base-case
analysis the following assumptions were made: (i) For each
type of chemo-radiotherapy strategy, the treatment affects all
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Table 2. List of Input Parameters for Resource Use, Unit Costs, and Utilities.
Point estimate SE (alpha, beta) Source
Resource use
Radiotherapy
Number of fractions SRT1/CRT1 31 1,89 Data (13)
Number of fractions SRT2 36 5,71 Data (13)
Number of fractions CRT2 24 5,71 (16)
Contouring PET-imaging (hours) 1,5 Expert opinion
Adverse events
Days of medication dysphagia 30 (17)
Days of hospital admission with dysphagia 2 (13,33; 0,15) (17)
Days of tube feeding with dysphagia 22 (220,50; 0,10) (17)
Days of irreversible dyspnea lifelong
Outpatient Visits (17)
Year 1 4
Year 2 2
Year 3 1
Costs (EUR) (Source) year of conversion
Treatment
Radiotherapy per fraction 244 16,95 (17) 2010
PET-scan 1325 (9) 2012
PET contouring, per hour 54,25 Based on yearly income ‘laborant’
Outpatient visits 60 (18) 2010
Chemotherapy (total costs) Supplementary Table 4
SRT1 2768
SRT2 2768
CRT1 4014
CRT2 6590
End-of-life care costs in cancer per year (palliative care only) 6603 737 (19) 2000
Toxicity
Medication dysphagia per day 2.80 (17) 2012
Treatment irreversible dyspnea per year 1140 112 (17) 2000
Replacing/removing tube 105 (18) 2009
Tube feeding per day 25 (17) 2009
Antibiotics, per course 83 (20) 2008
Blood transfusion 88 (21) 2006
G-CSF, per course 1,737 (20) 2008
Hospital admission per night 462 (18) 2010
Outpatient day 263 (18) 2010
Utilities Source
Reference value 0,82 0,067 (22)
Disutility any adverse event RT 0,35 0,05 (17,23)
Disutility hematologic toxicity 0.24 (17,23)
SRT1, conventional sequential chemo-radiation; CRT1, conventional concurrent chemo-radiation; SRT2, sequential PET-CT-based isotoxic acceler-
ated chemo-radiation; CRT2, concurrent chemo-radiation with daily low-dose cisplatin administration and daily radiation; SE, standard error; RT,
radiotherapy; G-CSF, granulocyte colony-stimulating factor.
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Table 3. Base-Case Scenario: Model Predictions for the Four Radiotherapy Strategies over a 3-Year Time Horizon (N= 50,000) and ICERs and ICURs Compared
to the Reference Strategy and Compared to the Next Best Cost-Effective Strategy.
SRT1 CRT1 SRT2 CRT2
Survival (%)
1 year 0.49 0.60 0.62 0.65
2 years 0.20 0.29 0.39 0.44
3 years 0.18 0.21 0.30 0.37
Recurrence at 3 years (%)
LR 0.13 0.08 0.11 0.28
DM 0.62 0.66 0.50 0.51
Toxicity at 3 years (%)
Dysphagia 0.04 0.26 0.09 0.15
Dyspnea 0.05 0.04 0.10 0.07
Neutropenia 0.42 0.55 0.42 0.03
Anemia 0.18 0.15 0.18 0
Undiscounted LYs, QALYs, and costs at 3 years
Total LY 1.38 1.44 1.77 1.78
Total QALYs 1.10 1.15 1.40 1.40
Total costs (€) 17288 18756 19072 17360
Discounted LYs, QALYs, and costs at 3 years
Total LY 1.37 1.42 1.75 1.75
Total QALYs 1.09 1.13 1.38 1.38
Total costs (€) 17156 18627 18958 17257
Cost-effectiveness and cost-utility compared to SRT1
ICER (€/LY) 29814 4708 263
ICUR (€/QALY) 38024 6249 346
Incremental analysis: cost-effectiveness and cost-utility compared to next best strategy
ICER (€/LY) NA Dominateda Dominateda 263b
ICUR (€/QALY) NA Dominateda Dominateda 346b
aThrough extended dominance.
bCompared to SRT1.
NA, not applicable; SRT1, conventional sequential chemo-radiation; CRT1, conventional concurrent chemo-radiation; SRT2, sequential PET-CT-based isotoxic acceler-
ated chemo-radiation; CRT2, concurrent chemo-radiation with daily low-dose cisplatin administration and daily radiation; CI, confidence interval; ICER, incremental
cost effectiveness ratio; LY, life-years; ICUR, incremental cost-utility ratio; QALYS, quality-adjusted life-years; LR, local recurrence; DM, distant metastasis.
transitions and this effect is different for each transition. (ii)
In all treatment strategies, patients have similar resource use
after the end of chemo-radiotherapy treatment (with the ex-
ception of toxicity-related resource use). (iii) Toxicities can
overlap. (iv) All deaths within the time horizon are caused by
cancer.
Model outcomes included predictions of survival, and pro-
portions of patients experiencing dysphagia, dyspnea, neu-
tropenia and anemia in the treatment period. Costs(discounted),
life-years (LYs) lived and quality-adjusted life-years (QALYs)
lived within a 3-year time horizon are the main model out-
comes used for the cost-effectiveness calculations. A time
horizon of 3 years was deemed appropriate for this patient
group, because in the data more than 80 percent of lung can-
cer deaths had already occurred within this period. For dis-
counting of the results, a 3 percent discount rate per year was
used.
The incremental cost-effectiveness ratio (ICER) and incre-
mental cost-utility ratio (ICUR) were calculated as the ratio be-
tween the difference in costs and the difference in either LYs
or QALYs between each strategy and the comparator strategy.
SRT1 was used as the comparator strategy. In addition, an in-
cremental analysis was done, in which all strategies were com-
pared with the next best nondominated strategy. A strategy is
dominated if there is an alternative strategy that is more effec-
tive at equal or lower costs. We used the term “dominant” if a
strategy was more effective at equal or lower costs than all other
strategies evaluated.
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According to the World Health Organization, a strategy is
considered highly cost effective if the ICUR does not exceed
the value of once the gross domestic product per capita pur-
chasing power parity (GDP) of a country. This means a thresh-
old value of EUR 30,491 per QALY in Europe (24).
Scenarios and Sensitivity Analyses
To assess the impact of uncertainty in model parameters on the
results of the cost-effectiveness analysis, ideally a probabilis-
tic sensitivity analysis is carried out. However, when combin-
ing a statistical model with calibration, the uncertainty of the
calibrated parameters as well as the correlation among all pa-
rameters in the model is unknown, precluding a mathematically
sound probabilistic sensitivity analysis. To assess the possible
consequences of model uncertainties, we, therefore, carried out
two scenario analyses and four sensitivity analyses. First, we
obtained model predictions for a different patient cohort, that
is, a cohort with patients in better physical condition; we as-
sumed that all patients had a WHO performance status of 0 or
1, and that 75 percent of the patients had more than two affected
lymph nodes. We assumed that the mean GTV was 100 cc3. In
general, this profile was seen in patients eligible for concurrent
chemo-radiation in data and literature (13). In the second sce-
nario, we set the costs and disutilities for toxicities to zero.
In the first sensitivity analysis, we studied the impact of us-
ing alternative sets of five HRs for the treatment effect of SRT2,
CRT1, and CRT2 compared with SRT1. To be more specific, we
selected for SRT2, CRT1, and CRT2 sets of HRs that resulted in
model predictions corresponding to the lower and upper band
of the 95 percent confidence interval (CI) of the data-based sur-
vival curve.
Furthermore, we decreased disutilities for toxicities with
50 percent (sensitivity analysis 2) and varied the costs of treat-
ment for toxicities with -50 percent and +50 percent (sensitiv-
ity analysis 3). Because costs of end-of-life care were assigned
to patients that died within the time horizon of the model, we
also varied the costs of end-of-life care with –50 percent and
+50 percent (sensitivity analysis 4).
RESULTS
Base-case Scenario
The results of the base-case scenario in which the distribu-
tion of clinical and tumor features was held constant over the
four strategies, are presented in Table 3. Predicted discounted
average survival in the base-scenario was 1.37 LY for SRT1,
1.42 LY for CRT1, 1.75 LY for SRT2, and 1.75 LY for CRT2.
The discounted QALYs followed the same ranking, from 1.09
for SRT1, 1.13 for CRT1, 1.38 for SRT2, and 1.38 for CRT2.
Discounted costs of SRT1 were estimated to be EUR
17,156, followed by CRT2 (EUR 17,257), CRT1 (EUR 18,627),
and SRT2 (EUR 18,958). Costs for radiotherapy were highest
in SRT1 (EUR 8,716) and lowest in CRT2 (EUR 5,864) due to
the number of fractions in each strategy. Costs of chemother-
apy were highest in CRT2 (EUR 6,590) and lowest in SRT1
and SRT2 (both EUR 2,768). Other cost differences are the ad-
ditional PET-scan for treatment planning in SRT2 (EUR 1,406)
and costs of end-of-life care, which are highest in SRT1 (EUR
5,645) and lowest in CRT2 (EUR 4,191). A break-down of the
costs in the base-case analysis for each strategy can be found in
Supplementary Table 5.
As shown in Table 3, the ICER and ICUR compared
with reference strategy SRT1, were EUR 29,814/LY and
EUR 38,024/QALY for CRT1, EUR 4,708/LY and EUR
6,249/QALY for SRT2, and EUR 263/LY and EUR 346/QALY
for CRT2, respectively. CRT1 was dominated by SRT2 and
CRT2 because it produces fewer LYs gained (or QALYs) at
higher costs than both these strategies. Considering the afore-
mentioned threshold value of EUR 30,439, SRT2 and CRT2
can be considered highly cost-effective compared with SRT1.
However, CRT2 was the most cost-effective strategy. This strat-
egy was not only highly cost-effective compared with reference
strategy SRT1, but also more or as effective and less costly than
the other two alternative strategies.
Scenarios and Sensitivity Analyses
The impact of the scenario and sensitivity analyses on dis-
counted costs and QALYs are summarized in the tornado di-
agrams in Supplementary Figure 5. Additional results concern-
ing ICERs and ICURs compared with SRT1 and those resulting
from the incremental analyses can be found in Supplementary
Table 6. When the four strategies were evaluated for a patient
cohort with a different case-mix, we found that CRT2 dom-
inated both SRT1 and CRT1. SRT2 was slightly more effec-
tive than CRT2, but the ICUR compared with CRT2 was EUR
55,746 per QALY, which is above the Dutch willingness-to-
pay threshold of EUR 30,491 per QALY. In scenario 4, with
costs and disutilities for toxicities set to zero, cost-differences
between the concurrent strategies and SRT1 were affected
compared with the base-case analysis, but the overall cost-
effectiveness results were very similar.
Of all sensitivity analyses, the first analysis in which CRT1,
SRT2, and CRT2 were simulated with parameter sets reflect-
ing the lower and upper CI for survival, had the largest impact
on cost- and QALY differences. Nevertheless, in all sensitiv-
ity analyses, we found similar rankings for incremental cost-
effectiveness as in the base-case scenario. That is, CRT2 was ei-
ther the dominant strategy (being more effective and less costly
than all other strategies), or was highly cost-effective compared
with SRT1.
DISCUSSION
Compared with conventional sequential chemo-radiotherapy
(SRT1), sequential isotoxic accelerated chemo-radiotherapy
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as well as standard concurrent chemo-radiotherapy and con-
current chemo-radiotherapy with a daily low-dose cisplatin
scheme are more effective and slightly costlier. In general,
cost-differences between strategies were small. Concurrent
chemo-radiotherapy with daily low-dose cisplatin was the
most effective strategy, and was also less costly than stan-
dard chemo-radiotherapy and sequential isotoxic accelerated
chemo-radiotherapy. This means that the latter two strategies
were dominated by concurrent chemo-radiotherapy with daily
low-dose cisplatin. When assuming conservative treatment ef-
fects, we found that concurrent chemo-radiotherapy with daily
low-dose cisplatin is still the most effective and cost-effective
strategy.
Existing Evidence
Where SRT1 and CRT1 are fully implemented strategies in
the treatment of NSCLC, SRT2 aims at an individually es-
calated dose and CRT2 aims to enhance the effects of irra-
diation by the radio sensitizing effect of cisplatin. For these
strategies evidence is available regarding improved local tu-
mor control. Evidence on survival and quality of life is lim-
ited (25;26). This is the first study to assess the comparative
cost-effectiveness of these specific chemo-radiation schemes.
By using a model-based analysis, we predicted effectiveness
and cost-effectiveness on clinical outcomes, such as survival
and quality of life outcomes, and costs. We found two model-
based study studies that evaluated radiotherapy schemes in the
literature (27;28). One study found that a hyperfractionated and
accelerated scheme was cost-effective compared with conven-
tional radiotherapy in Belgium (27). Another study compared
various types of accelerated and hyperfractionated schemes,
and found that modified schemes were more effective than con-
ventional radiotherapy, at higher costs (28). However, none of
these studies assessed a strategy with an isotoxic dosing scheme
or a low-dose chemotherapy scheme specifically.
Model Challenges
The micro-simulation model that was used in this study was
based on a multi-state statistical model that was directly de-
rived from data. To adapt the model to allow simulation of the
four chemo-radiotherapy schemes, we used calibration. Our ap-
proach is new because it brings together statistical modeling
techniques and calibration to assess the required parameters in
a micro-simulation model. This new approach came with sev-
eral challenges. First, the micro-simulation model was initially
quantified with data on patients that either received sequential
chemo-radiotherapy or received radiotherapy alone. To verify
validity of the model for patients that receive sequential chemo-
radiotherapy only, we obtained model predictions for this par-
ticular subgroup of patients and compared those with outcomes
for the corresponding subset of patients in the data. The results
of this model validation are presented in the Supplementary
Materials. Overall, model fit is reasonable, although the shape
of the model-predicted survival curves differs from the data-
based survival curves, probably mainly due to semi-parametric
assumptions underlying the micro-simulation model.
Second, the micro-simulation model did not include pa-
rameters specifying the effect of concurrent chemo-radiation
compared with the reference strategy for the five model tran-
sitions. These parameters were estimated by calibration. The
calibration targets were obtained from the literature. It should
be noted that in the meta-analysis that was used for calibration
of CRT1, two studies were included that used a daily low dose
cisplatin regimen, comparable to our CRT2 strategy. Therefore,
the results of CRT1 may be a bit too optimistic. The treatment
effects of both CRT1 and CRT2 were calibrated while keeping
the other covariate effects in the model (WHO performance sta-
tus, lymph node status, GTV) constant. It is probably not fully
correct to assume that parameter estimates for the other covari-
ates in the model hold also in the presence of the concurrent
treatment effects.
Third, although potential differences in baseline character-
istics were taken into account in the model, not all factors caus-
ing heterogeneity were included. For example, staging of pa-
tients was slightly different over the treatment strategies. The
histology of patients, as well as age and proportion of females
was similar over the four strategies.
Fourth, an important advantage of using a statistical model
to inform the entire micro-simulation model is that parame-
ter uncertainty can be assessed while accounting for the joint
correlation between parameters. When combining a statistical
model with calibration, however, the actual uncertainty of the
calibrated parameters is unknown. Therefore, a mathematically
sound probabilistic sensitivity analysis taking the correlation
among parameters into account is no longer possible. It was
shown previously that ignoring the correlation among param-
eters when carrying out a probabilistic sensitivity analysis of
a microsimulation model leads to uncertainty bounds that are
excessively inflated (29). To assess the possible consequences
of model uncertainties, we, therefore, carried out scenario and
sensitivity analyses. In all these analyses, we found a similar
ranking in costs and effects as in the base-case-scenario.
Study Limitations
This study has several limitations. First, the health-care per-
spective was used instead of a societal perspective. Therefore,
loss of productivity at work was not incorporated, nor the pa-
tient burden related to the number of hospital visits for each
(chemo-)radiotherapy administration. Second, we used a time
horizon of 3 years instead of a lifelong time horizon. However,
because in the data more than 80 percent of lung cancer deaths
had already occurred within 3 years, this time horizon seems
appropriate for this patient group. Finally, our study was carried
out in a Dutch health-care setting, using mainly Dutch sources
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for costs and resource use. Although costs vary widely over
countries due to varying health care settings, the results of the
scenario analyses showed that varying cost parameters does not
change the ranking in cost-effectiveness, and does not change
the treatment decision. Therefore, we believe that if this study
was conducted in another country with different unit costs, the
ranking in cost-effectiveness of the treatment strategies is likely
to be similar to our base-case scenario.
Study Results in the Dutch Context
According to the Dutch guidelines, eligible patients for
chemotherapy and radiotherapy are preferentially treated with
concurrent chemotherapy and radiotherapy. In less fit patients,
sequential chemo-radiotherapy is given and obviously the older
or frail patients are treated with radiation alone or palliatively
(30).
This study provides indications that sequential isotoxic ac-
celerated chemo-radiotherapy is a more effective and cost-
effective treatment option than conventional concurrent or
sequential chemo-radiotherapy. However, concurrent chemo-
radiotherapy with a daily low-dose cisplatin regimen may be
a better option for physically fit nonmetastatic NSCLC patients
ineligible for surgery, because of improved survival, quality of
life, and cost-effectiveness.
Data from the Dutch Cancer Registry (www.iknl.nl) indi-
cate that, in The Netherlands, roughly 1,000 inoperable stage
III NSCLC patients are yearly treated with either concurrent
(55 percent) or sequential (45 percent) chemo-radiotherapy. If
the conventional concurrent regimen would be replaced with
concurrent chemo-radiotherapy with a daily low-dose cisplatin
regimen, this would amount to yearly cost-savings of roughly
EUR 770,00 while gaining 138 QALYs. If the yearly 450
NSCLC patients who currently receive conventional sequential
chemo-radiotherapy would receive sequential isotoxic acceler-
ated chemo-radiotherapy, this would cost EUR 800,00 while
gaining 135 QALYs. In case the latter subgroup would toler-
ate the concurrent low-dose cisplatin scheme, because of de-
creased toxicity compared with the conventional scheme, this
would cost only 32,000 Euro yearly for the same health gain of
135 QALYs.
CONCLUSIONS
Optimized sequential and concurrent chemo-radiation strate-
gies are more effective and cost-effective than conventional se-
quential and concurrent strategies. Concurrent chemo-radiation
with a daily low-dose cisplatin regimen is the most cost-
effective treatment option for nonmetastatic NSCLC patients
ineligible for surgery. For patients, that are physically not
fit enough to receive concurrent chemo-radiation, sequential
isotoxic accelerated chemo-radiotherapy is a good and cost-
effective alternative option.
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